{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T01:09:30Z","timestamp":1712192970615},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,3]]},"DOI":"10.7759\/cureus.57507","type":"journal-article","created":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T10:59:02Z","timestamp":1712141942000},"source":"Crossref","is-referenced-by-count":0,"title":["Differences in Sterile Inflammation Incidence After Trabectedin Infusion With Two Central Venous Port Systems: A Retrospective Study"],"prefix":"10.7759","author":[{"given":"Takatoshi","family":"Kubo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichiro","family":"Yasaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.777872","article-title":"The role of trabectedin in soft tissue sarcoma","volume":"13","author":"Nakamura T","year":"2022","unstructured":"Nakamura T, Sudo A. The role of trabectedin in soft tissue sarcoma. Front Pharmacol. 2022, 13:10.3389\/fphar.2022.777872","journal-title":"Front Pharmacol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.07.006","article-title":"Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2606","volume":"32","author":"Gronchi A","year":"2021","unstructured":"Gronchi A, Miah AB, Dei Tos AP, et al.. Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2606. Ann Oncol. 2021, 32:1348-65. 10.1016\/j.annonc.2021.07.006","journal-title":"Ann Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.4734","article-title":"Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial","volume":"34","author":"Demetri GD","year":"2016","unstructured":"Demetri GD, von Mehren M, Jones RL, et al.. Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial. J Clin Oncol. 2016, 34:786-93. 10.1200\/JCO.2015.62.4734","journal-title":"J Clin Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-016-0344-3","article-title":"Trabectedin for soft tissue sarcoma: current status and future perspectives","volume":"33","author":"Gordon EM","year":"2016","unstructured":"Gordon EM, Sankhala KK, Chawla N, Chawla SP. Trabectedin for soft tissue sarcoma: current status and future perspectives. Adv Ther. 2016, 33:1055-71. 10.1007\/s12325-016-0344-3","journal-title":"Adv Ther"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2217\/fon.15.76","article-title":"Trabectedin clinical cases: use according to indication in diverse clinical scenarios","volume":"11","author":"Grignani G","year":"2015","unstructured":"Grignani G, Mart\u00edn-Broto J, Schuler M, Reichardt P. Trabectedin clinical cases: use according to indication in diverse clinical scenarios. Future Oncol. 2015, 11:15-24. 10.2217\/fon.15.76","journal-title":"Future Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00908","article-title":"Neoadjuvant chemotherapy in high-grade myxoid liposarcoma: results of the expanded cohort of a randomized trial from Italian (ISG), Spanish (GEIS), French (FSG), and Polish sarcoma groups (PSG)","volume":"42","author":"Gronchi A","year":"2024","unstructured":"Gronchi A, Palmerini E, Quagliuolo V, et al.. Neoadjuvant chemotherapy in high-grade myxoid liposarcoma: results of the expanded cohort of a randomized trial from Italian (ISG), Spanish (GEIS), French (FSG), and Polish sarcoma groups (PSG). J Clin Oncol. 2024, 42:898-906. 10.1200\/JCO.23.00908","journal-title":"J Clin Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1159\/000335879","article-title":"Administration of 24-h intravenous infusions of trabectedin in ambulatory patients with mesenchymal tumors via disposable elastomeric pumps: an effective and patient-friendly palliative treatment option","volume":"35","author":"Sch\u00f6ffski P","year":"2012","unstructured":"Sch\u00f6ffski P, Cerbone L, Wolter P, et al.. Administration of 24-h intravenous infusions of trabectedin in ambulatory patients with mesenchymal tumors via disposable elastomeric pumps: an effective and patient-friendly palliative treatment option. Onkologie. 2012, 35:14-7. 10.1159\/000335879","journal-title":"Onkologie"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.0088","article-title":"Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules","volume":"27","author":"Demetri GD","year":"2009","unstructured":"Demetri GD, Chawla SP, von Mehren M, et al.. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol. 2009, 27:4188-96. 10.1200\/JCO.2008.21.0088","journal-title":"J Clin Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0898","article-title":"FDA approval summary: trabectedin for unresectable or metastatic liposarcoma or leiomyosarcoma following an anthracycline-containing regimen","volume":"23","author":"Barone A","year":"2017","unstructured":"Barone A, Chi DC, Theoret MR, et al.. FDA approval summary: trabectedin for unresectable or metastatic liposarcoma or leiomyosarcoma following an anthracycline-containing regimen. Clin Cancer Res. 2017, 23:7448-53. 10.1158\/1078-0432.CCR-17-0898","journal-title":"Clin Cancer Res"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32462","article-title":"Safety and efficacy of trabectedin when administered in the inpatient versus outpatient setting: clinical considerations for outpatient administration of trabectedin","volume":"125","author":"Jones RL","year":"2019","unstructured":"Jones RL, Maki RG, Patel SR, et al.. Safety and efficacy of trabectedin when administered in the inpatient versus outpatient setting: clinical considerations for outpatient administration of trabectedin. Cancer. 2019, 125:4435-41. 10.1002\/cncr.32462","journal-title":"Cancer"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.6473","article-title":"Recognition of a new chemotherapeutic vesicant: trabectedin (ecteinascidin-743) extravasation with skin and soft tissue damage","volume":"27","author":"Theman TA","year":"2009","unstructured":"Theman TA, Hartzell TL, Sinha I, et al.. Recognition of a new chemotherapeutic vesicant: trabectedin (ecteinascidin-743) extravasation with skin and soft tissue damage. J Clin Oncol. 2009, 27:e198-200. 10.1200\/JCO.2008.21.6473","journal-title":"J Clin Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s13569-017-0066-6","article-title":"Central venous access related adverse events after trabectedin infusions in soft tissue sarcoma patients; experience and management in a nationwide multi-center study","volume":"7","author":"Verboom MC","year":"2017","unstructured":"Verboom MC, Ouwerkerk J, Steeghs N, et al.. Central venous access related adverse events after trabectedin infusions in soft tissue sarcoma patients; experience and management in a nationwide multi-center study. Clin Sarcoma Res. 2017, 7:2. 10.1186\/s13569-017-0066-6","journal-title":"Clin Sarcoma Res"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.875695","article-title":"Determination of extravasation effects of nal-Iri and trabectedin and evaluation of treatment options for trabectedin extravasation in a preclinical animal model","volume":"13","author":"Keritam O","year":"2022","unstructured":"Keritam O, Juhasz V, Sch\u00f6fer C, et al.. Determination of extravasation effects of nal-Iri and trabectedin and evaluation of treatment options for trabectedin extravasation in a preclinical animal model. Front Pharmacol. 2022, 13:10.3389\/fphar.2022.875695","journal-title":"Front Pharmacol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1177\/088532828900400101","article-title":"Development of Anthron, an antithrombogenic coating for angiographic catheters","volume":"4","author":"Nagaoka S","year":"1989","unstructured":"Nagaoka S, Noishiki Y. Development of Anthron, an antithrombogenic coating for angiographic catheters. J Biomater Appl. 1989, 4:3-21. 10.1177\/088532828900400101","journal-title":"J Biomater Appl"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1177\/088532828900400102","article-title":"Evaluation of antithrombogenic thermodilution catheter","volume":"4","author":"Nagaoka S","year":"1989","unstructured":"Nagaoka S, Mikami M, Noishiki Y. Evaluation of antithrombogenic thermodilution catheter. J Biomater Appl. 1989, 4:22-32. 10.1177\/088532828900400102","journal-title":"J Biomater Appl"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/238350-differences-in-sterile-inflammation-incidence-after-trabectedin-infusion-with-two-central-venous-port-systems-a-retrospective-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T10:59:49Z","timestamp":1712141989000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/238350-differences-in-sterile-inflammation-incidence-after-trabectedin-infusion-with-two-central-venous-port-systems-a-retrospective-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,3]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.57507","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4,3]]}}}